Presurgical Staging of Non-small Cell Lung Cancer

Halpern, Benjamin S.; Schiepers, Christiaan; Weber, Wolfgang; Crawford, Tyler L.; Fueger, Barbara J.; Phelps, Michael E.; Czernin, Johannes

doi:10.1016/s0012-3692(15)52634-2

Cited by 93 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The brain and the skeleton are investigated in patients whose symptoms raise the suspicion of metastatic disease or in whom curative treatment is considered. PET in combination with CT (PET-CT) for the staging of lung cancer combines high sensitivity with specificity and is an emerging method for staging in particular for the selection of patients for curative treatment [6].…”

Section: Imaging Techniquesmentioning

confidence: 99%

Consensus on medical treatment of non-small-cell lung cancer—update 2004

Zielinski

Beinert²,

Crawford

et al. 2005

Lung Cancer

View full text Add to dashboard Cite

Section: Imaging Techniquesmentioning

confidence: 99%

Consensus on medical treatment of non-small-cell lung cancer—update 2004

Zielinski

Beinert²,

Crawford

et al. 2005

Lung Cancer

View full text Add to dashboard Cite

PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer

Schmidt‐Hansen

Baldwin

Hasler

et al. 2014

Cochrane Database of Systematic Reviews

149

136

View full text Add to dashboard Cite

show abstract

Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non–small‐cell lung cancer patients

Zhang

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

In the recent years, fluorine 18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT) has emerged as a new modality for staging non-small-cell lung cancer (NSCLC) patients. The aim of this meta-analysis was to assess the diagnostic value of 18 F-FDG PET/CT in detecting metastatic lesions in NSCLC patients. Meta-analysis methods were used to pool sensitivity, specificity, positive and negative likehood ratios, diagnostic odd ratios and to construct a summary receiver-operating characteristic curve. Data from included studies were pooled to compare the diagnostic accuracy between PET/CT and PET or CT alone in nodal staging. Totally, 56 studies involving 8,699 patients met the inclusion criteria. Lung cancer is the leading cause of tumor-related deaths worldwide, and non-small-cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. 1 The current criteria for staging NSCLC is based on the TNM system, 2 which determines treatment options and predicts survival. 3 So, staging NSCLC is important, and accurate clinical methods are in great need. Various diagnostic methods have been used for staging NSCLC. [4][5][6][7] Computed tomography (CT) has been widely used to evaluate the nodal status of lung cancer based on the size or shape of the lymph nodes. 8 However, the sensitivity and the specificity were relatively low, because the lymph node size may not correlate with the presence of metastatic disease. 9 Based on the fact that malignant cells show higher rates of glycolysis than most surrounding normal structures, 10 fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been introduced and developed as an effective modality for tumor staging in a variety of cancers. 11 However, PET has relatively poor spatial resolution, thus limits its anatomical localization of lesions. 12 Mediastinoscopy, endobronchial and endoscopic ultrasound, and other surgical procedures are frequently used for thoracic nodal evaluation in lung cancer, but these techniques are invasive and cumbersome. 7,13 In the past recent years, 18 F-FDG PET/CT has emerged as a new modality for staging NSCLC patients. 4,14 The aim of this study was to evaluate the diagnostic accuracy of 18 F-FDG PET/CT in detecting metastases in NSCLC patients. Material and Methods Selection criteriaSelection criteria were given as follows: (1) 18 F-FDG PET/CT was used for the evaluation of lymph node (LN) metastases or extrapulmonary metastases in NSCLC; (2) histologic assessment should be applied as reference standard for LN metastases; for studies evaluated extrathoracic metastases, other reference standards such as imaging modality, radiological and clinical follow-up were also applied; (3) absolute numbers of true-positive (TP), false-positive (FP), true-

show abstract

Presurgical Staging of Non-small Cell Lung Cancer

Cited by 93 publications

References 20 publications

Consensus on medical treatment of non-small-cell lung cancer—update 2004

Consensus on medical treatment of non-small-cell lung cancer—update 2004

PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer

Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non–small‐cell lung cancer patients

Contact Info

Product

Resources

About